Oncology and Hematology News and Journal Articles
Recent Content
Men who used sildenafil (Viagra) had an 84% increased risk for developing melanoma, even after adjusting for known risk factors, according to the results of a prospective study.
A study of patient preference revealed that patients who participated in a crossover trial of pazopanib and sunitinib for metastatic renal cell carcinoma preferred treatment with pazopanib.
Living alone increased a man’s risk for being diagnosed with later stage melanoma by more than 40%, according to the results of a recent Swedish study.
A high body mass index prior to a colorectal cancer diagnosis is linked to a higher risk of death, even when the patient’s tumor type is generally associated with a better prognosis.
The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).
Two early trials studying CDK inhibitors in metastatic breast cancer have shown impressive activity in HR-positive disease, according to data presented at the AACR annual meeting.
At the ACCC annual meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
At the ACCC 40th Annual National Meeting, David Evans, RN, MSN, MBA, discussed some of the top reimbursement issues that cancer centers face when it some to clinical trials.
Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II
Major studies looking at breast cancer screening with mammography may have more consistent findings than previously thought.
In this interview we preview the 2014 annual meeting of the Association of Community Cancer Centers with Matthew Farber, director of provider economics and public policy for the association.
In this interview we discuss the role of early treatment, active surveillance, and watchful waiting in patients with PSA-detected early-stage prostate cancer.
In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.
In this interview, we discuss the current state of pancreatic cancer management, and look toward trials to further define the best course of treatment for this deadly disease.
